Global Cannabinoid Derived Pharmaceutical Market Growth 2026-2032
The global Cannabinoid Derived Pharmaceutical market size is predicted to grow from US$ 1125 million in 2025 to US$ 2586 million in 2032; it is expected to grow at a CAGR of 12.9% from 2026 to 2032.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the ?Cannabinoid Derived Pharmaceutical Industry Forecast? looks at past sales and reviews total world Cannabinoid Derived Pharmaceutical sales in 2025, providing a comprehensive analysis by region and market sector of projected Cannabinoid Derived Pharmaceutical sales for 2026 through 2032. With Cannabinoid Derived Pharmaceutical sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cannabinoid Derived Pharmaceutical industry.
This Insight Report provides a comprehensive analysis of the global Cannabinoid Derived Pharmaceutical landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cannabinoid Derived Pharmaceutical portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Cannabinoid Derived Pharmaceutical market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cannabinoid Derived Pharmaceutical and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cannabinoid Derived Pharmaceutical.
This report presents a comprehensive overview, market shares, and growth opportunities of Cannabinoid Derived Pharmaceutical market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the ?Cannabinoid Derived Pharmaceutical Industry Forecast? looks at past sales and reviews total world Cannabinoid Derived Pharmaceutical sales in 2025, providing a comprehensive analysis by region and market sector of projected Cannabinoid Derived Pharmaceutical sales for 2026 through 2032. With Cannabinoid Derived Pharmaceutical sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cannabinoid Derived Pharmaceutical industry.
This Insight Report provides a comprehensive analysis of the global Cannabinoid Derived Pharmaceutical landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cannabinoid Derived Pharmaceutical portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Cannabinoid Derived Pharmaceutical market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cannabinoid Derived Pharmaceutical and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cannabinoid Derived Pharmaceutical.
This report presents a comprehensive overview, market shares, and growth opportunities of Cannabinoid Derived Pharmaceutical market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Cannabinoid Receptor Type 1 (CB1)
- Cannabinoid Receptor Type 2 (CB2)
- Others
- Epilepsy
- Migraine
- Multiple Sclerosis
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Cara Therapeutics Inc
- Arena Pharmaceuticals
- Cannabics Pharmaceuticals Inc
- Echo Pharmaceuticals
- Gw Pharmaceuticals
- Inmed Pharmaceuticals
- Insys Therapeutics Inc
- Larapharm
- Mgc Pharmaceuticals Ltd
- One World Cannabis
- Orpheus Medica
- Receptor Life Sciences
- Respirerx Pharmaceuticals
- Tetra Bio-Pharma
- Cardiol Therapeutics
- United Cannabis Corporation
- Zynerba Pharmaceuticals
- What is the 10-year outlook for the global Cannabinoid Derived Pharmaceutical market?
- What factors are driving Cannabinoid Derived Pharmaceutical market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Cannabinoid Derived Pharmaceutical market opportunities vary by end market size?
- How does Cannabinoid Derived Pharmaceutical break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Cannabinoid Derived Pharmaceutical Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Cannabinoid Derived Pharmaceutical by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Cannabinoid Derived Pharmaceutical by Country/Region, 2021, 2025 & 2032
2.2 Cannabinoid Derived Pharmaceutical Segment by Type
2.2.1 Cannabinoid Receptor Type 1 (CB1)
2.2.2 Cannabinoid Receptor Type 2 (CB2)
2.2.3 Others
2.2.4 Cannabinoid Derived Pharmaceutical Sales by Type
2.2.4.1 Global Cannabinoid Derived Pharmaceutical Sales Market Share by Type (2021-2026)
2.2.4.2 Global Cannabinoid Derived Pharmaceutical Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Cannabinoid Derived Pharmaceutical Sale Price by Type (2021-2026)
2.3 Cannabinoid Derived Pharmaceutical Segment by Application
2.3.1 Epilepsy
2.3.2 Migraine
2.3.3 Multiple Sclerosis
2.3.4 Others
2.3.5 Cannabinoid Derived Pharmaceutical Sales by Application
2.3.5.1 Global Cannabinoid Derived Pharmaceutical Sale Market Share by Application (2021-2026)
2.3.5.2 Global Cannabinoid Derived Pharmaceutical Revenue and Market Share by Application (2021-2026)
2.3.5.3 Global Cannabinoid Derived Pharmaceutical Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Cannabinoid Derived Pharmaceutical Breakdown Data by Company
3.1.1 Global Cannabinoid Derived Pharmaceutical Annual Sales by Company (2021-2026)
3.1.2 Global Cannabinoid Derived Pharmaceutical Sales Market Share by Company (2021-2026)
3.2 Global Cannabinoid Derived Pharmaceutical Annual Revenue by Company (2021-2026)
3.2.1 Global Cannabinoid Derived Pharmaceutical Revenue by Company (2021-2026)
3.2.2 Global Cannabinoid Derived Pharmaceutical Revenue Market Share by Company (2021-2026)
3.3 Global Cannabinoid Derived Pharmaceutical Sale Price by Company
3.4 Key Manufacturers Cannabinoid Derived Pharmaceutical Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Cannabinoid Derived Pharmaceutical Product Location Distribution
3.4.2 Players Cannabinoid Derived Pharmaceutical Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR CANNABINOID DERIVED PHARMACEUTICAL BY GEOGRAPHIC REGION
4.1 World Historic Cannabinoid Derived Pharmaceutical Market Size by Geographic Region (2021-2026)
4.1.1 Global Cannabinoid Derived Pharmaceutical Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Cannabinoid Derived Pharmaceutical Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Cannabinoid Derived Pharmaceutical Market Size by Country/Region (2021-2026)
4.2.1 Global Cannabinoid Derived Pharmaceutical Annual Sales by Country/Region (2021-2026)
4.2.2 Global Cannabinoid Derived Pharmaceutical Annual Revenue by Country/Region (2021-2026)
4.3 Americas Cannabinoid Derived Pharmaceutical Sales Growth
4.4 APAC Cannabinoid Derived Pharmaceutical Sales Growth
4.5 Europe Cannabinoid Derived Pharmaceutical Sales Growth
4.6 Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Growth
5 AMERICAS
5.1 Americas Cannabinoid Derived Pharmaceutical Sales by Country
5.1.1 Americas Cannabinoid Derived Pharmaceutical Sales by Country (2021-2026)
5.1.2 Americas Cannabinoid Derived Pharmaceutical Revenue by Country (2021-2026)
5.2 Americas Cannabinoid Derived Pharmaceutical Sales by Type (2021-2026)
5.3 Americas Cannabinoid Derived Pharmaceutical Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Cannabinoid Derived Pharmaceutical Sales by Region
6.1.1 APAC Cannabinoid Derived Pharmaceutical Sales by Region (2021-2026)
6.1.2 APAC Cannabinoid Derived Pharmaceutical Revenue by Region (2021-2026)
6.2 APAC Cannabinoid Derived Pharmaceutical Sales by Type (2021-2026)
6.3 APAC Cannabinoid Derived Pharmaceutical Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Cannabinoid Derived Pharmaceutical by Country
7.1.1 Europe Cannabinoid Derived Pharmaceutical Sales by Country (2021-2026)
7.1.2 Europe Cannabinoid Derived Pharmaceutical Revenue by Country (2021-2026)
7.2 Europe Cannabinoid Derived Pharmaceutical Sales by Type (2021-2026)
7.3 Europe Cannabinoid Derived Pharmaceutical Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Cannabinoid Derived Pharmaceutical by Country
8.1.1 Middle East & Africa Cannabinoid Derived Pharmaceutical Sales by Country (2021-2026)
8.1.2 Middle East & Africa Cannabinoid Derived Pharmaceutical Revenue by Country (2021-2026)
8.2 Middle East & Africa Cannabinoid Derived Pharmaceutical Sales by Type (2021-2026)
8.3 Middle East & Africa Cannabinoid Derived Pharmaceutical Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Cannabinoid Derived Pharmaceutical
10.3 Manufacturing Process Analysis of Cannabinoid Derived Pharmaceutical
10.4 Industry Chain Structure of Cannabinoid Derived Pharmaceutical
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Cannabinoid Derived Pharmaceutical Distributors
11.3 Cannabinoid Derived Pharmaceutical Customer
12 WORLD FORECAST REVIEW FOR CANNABINOID DERIVED PHARMACEUTICAL BY GEOGRAPHIC REGION
12.1 Global Cannabinoid Derived Pharmaceutical Market Size Forecast by Region
12.1.1 Global Cannabinoid Derived Pharmaceutical Forecast by Region (2027-2032)
12.1.2 Global Cannabinoid Derived Pharmaceutical Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Cannabinoid Derived Pharmaceutical Forecast by Type (2027-2032)
12.7 Global Cannabinoid Derived Pharmaceutical Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Cara Therapeutics Inc
13.1.1 Cara Therapeutics Inc Company Information
13.1.2 Cara Therapeutics Inc Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.1.3 Cara Therapeutics Inc Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Cara Therapeutics Inc Main Business Overview
13.1.5 Cara Therapeutics Inc Latest Developments
13.2 Arena Pharmaceuticals
13.2.1 Arena Pharmaceuticals Company Information
13.2.2 Arena Pharmaceuticals Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.2.3 Arena Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Arena Pharmaceuticals Main Business Overview
13.2.5 Arena Pharmaceuticals Latest Developments
13.3 Cannabics Pharmaceuticals Inc
13.3.1 Cannabics Pharmaceuticals Inc Company Information
13.3.2 Cannabics Pharmaceuticals Inc Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.3.3 Cannabics Pharmaceuticals Inc Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Cannabics Pharmaceuticals Inc Main Business Overview
13.3.5 Cannabics Pharmaceuticals Inc Latest Developments
13.4 Echo Pharmaceuticals
13.4.1 Echo Pharmaceuticals Company Information
13.4.2 Echo Pharmaceuticals Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.4.3 Echo Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Echo Pharmaceuticals Main Business Overview
13.4.5 Echo Pharmaceuticals Latest Developments
13.5 Gw Pharmaceuticals
13.5.1 Gw Pharmaceuticals Company Information
13.5.2 Gw Pharmaceuticals Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.5.3 Gw Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Gw Pharmaceuticals Main Business Overview
13.5.5 Gw Pharmaceuticals Latest Developments
13.6 Inmed Pharmaceuticals
13.6.1 Inmed Pharmaceuticals Company Information
13.6.2 Inmed Pharmaceuticals Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.6.3 Inmed Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Inmed Pharmaceuticals Main Business Overview
13.6.5 Inmed Pharmaceuticals Latest Developments
13.7 Insys Therapeutics Inc
13.7.1 Insys Therapeutics Inc Company Information
13.7.2 Insys Therapeutics Inc Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.7.3 Insys Therapeutics Inc Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Insys Therapeutics Inc Main Business Overview
13.7.5 Insys Therapeutics Inc Latest Developments
13.8 Larapharm
13.8.1 Larapharm Company Information
13.8.2 Larapharm Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.8.3 Larapharm Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Larapharm Main Business Overview
13.8.5 Larapharm Latest Developments
13.9 Mgc Pharmaceuticals Ltd
13.9.1 Mgc Pharmaceuticals Ltd Company Information
13.9.2 Mgc Pharmaceuticals Ltd Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.9.3 Mgc Pharmaceuticals Ltd Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Mgc Pharmaceuticals Ltd Main Business Overview
13.9.5 Mgc Pharmaceuticals Ltd Latest Developments
13.10 One World Cannabis
13.10.1 One World Cannabis Company Information
13.10.2 One World Cannabis Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.10.3 One World Cannabis Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 One World Cannabis Main Business Overview
13.10.5 One World Cannabis Latest Developments
13.11 Orpheus Medica
13.11.1 Orpheus Medica Company Information
13.11.2 Orpheus Medica Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.11.3 Orpheus Medica Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Orpheus Medica Main Business Overview
13.11.5 Orpheus Medica Latest Developments
13.12 Receptor Life Sciences
13.12.1 Receptor Life Sciences Company Information
13.12.2 Receptor Life Sciences Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.12.3 Receptor Life Sciences Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Receptor Life Sciences Main Business Overview
13.12.5 Receptor Life Sciences Latest Developments
13.13 Respirerx Pharmaceuticals
13.13.1 Respirerx Pharmaceuticals Company Information
13.13.2 Respirerx Pharmaceuticals Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.13.3 Respirerx Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Respirerx Pharmaceuticals Main Business Overview
13.13.5 Respirerx Pharmaceuticals Latest Developments
13.14 Tetra Bio-Pharma
13.14.1 Tetra Bio-Pharma Company Information
13.14.2 Tetra Bio-Pharma Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.14.3 Tetra Bio-Pharma Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Tetra Bio-Pharma Main Business Overview
13.14.5 Tetra Bio-Pharma Latest Developments
13.15 Cardiol Therapeutics
13.15.1 Cardiol Therapeutics Company Information
13.15.2 Cardiol Therapeutics Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.15.3 Cardiol Therapeutics Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Cardiol Therapeutics Main Business Overview
13.15.5 Cardiol Therapeutics Latest Developments
13.16 United Cannabis Corporation
13.16.1 United Cannabis Corporation Company Information
13.16.2 United Cannabis Corporation Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.16.3 United Cannabis Corporation Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 United Cannabis Corporation Main Business Overview
13.16.5 United Cannabis Corporation Latest Developments
13.17 Zynerba Pharmaceuticals
13.17.1 Zynerba Pharmaceuticals Company Information
13.17.2 Zynerba Pharmaceuticals Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.17.3 Zynerba Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Zynerba Pharmaceuticals Main Business Overview
13.17.5 Zynerba Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Cannabinoid Derived Pharmaceutical Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Cannabinoid Derived Pharmaceutical by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Cannabinoid Derived Pharmaceutical by Country/Region, 2021, 2025 & 2032
2.2 Cannabinoid Derived Pharmaceutical Segment by Type
2.2.1 Cannabinoid Receptor Type 1 (CB1)
2.2.2 Cannabinoid Receptor Type 2 (CB2)
2.2.3 Others
2.2.4 Cannabinoid Derived Pharmaceutical Sales by Type
2.2.4.1 Global Cannabinoid Derived Pharmaceutical Sales Market Share by Type (2021-2026)
2.2.4.2 Global Cannabinoid Derived Pharmaceutical Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Cannabinoid Derived Pharmaceutical Sale Price by Type (2021-2026)
2.3 Cannabinoid Derived Pharmaceutical Segment by Application
2.3.1 Epilepsy
2.3.2 Migraine
2.3.3 Multiple Sclerosis
2.3.4 Others
2.3.5 Cannabinoid Derived Pharmaceutical Sales by Application
2.3.5.1 Global Cannabinoid Derived Pharmaceutical Sale Market Share by Application (2021-2026)
2.3.5.2 Global Cannabinoid Derived Pharmaceutical Revenue and Market Share by Application (2021-2026)
2.3.5.3 Global Cannabinoid Derived Pharmaceutical Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Cannabinoid Derived Pharmaceutical Breakdown Data by Company
3.1.1 Global Cannabinoid Derived Pharmaceutical Annual Sales by Company (2021-2026)
3.1.2 Global Cannabinoid Derived Pharmaceutical Sales Market Share by Company (2021-2026)
3.2 Global Cannabinoid Derived Pharmaceutical Annual Revenue by Company (2021-2026)
3.2.1 Global Cannabinoid Derived Pharmaceutical Revenue by Company (2021-2026)
3.2.2 Global Cannabinoid Derived Pharmaceutical Revenue Market Share by Company (2021-2026)
3.3 Global Cannabinoid Derived Pharmaceutical Sale Price by Company
3.4 Key Manufacturers Cannabinoid Derived Pharmaceutical Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Cannabinoid Derived Pharmaceutical Product Location Distribution
3.4.2 Players Cannabinoid Derived Pharmaceutical Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR CANNABINOID DERIVED PHARMACEUTICAL BY GEOGRAPHIC REGION
4.1 World Historic Cannabinoid Derived Pharmaceutical Market Size by Geographic Region (2021-2026)
4.1.1 Global Cannabinoid Derived Pharmaceutical Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Cannabinoid Derived Pharmaceutical Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Cannabinoid Derived Pharmaceutical Market Size by Country/Region (2021-2026)
4.2.1 Global Cannabinoid Derived Pharmaceutical Annual Sales by Country/Region (2021-2026)
4.2.2 Global Cannabinoid Derived Pharmaceutical Annual Revenue by Country/Region (2021-2026)
4.3 Americas Cannabinoid Derived Pharmaceutical Sales Growth
4.4 APAC Cannabinoid Derived Pharmaceutical Sales Growth
4.5 Europe Cannabinoid Derived Pharmaceutical Sales Growth
4.6 Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Growth
5 AMERICAS
5.1 Americas Cannabinoid Derived Pharmaceutical Sales by Country
5.1.1 Americas Cannabinoid Derived Pharmaceutical Sales by Country (2021-2026)
5.1.2 Americas Cannabinoid Derived Pharmaceutical Revenue by Country (2021-2026)
5.2 Americas Cannabinoid Derived Pharmaceutical Sales by Type (2021-2026)
5.3 Americas Cannabinoid Derived Pharmaceutical Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Cannabinoid Derived Pharmaceutical Sales by Region
6.1.1 APAC Cannabinoid Derived Pharmaceutical Sales by Region (2021-2026)
6.1.2 APAC Cannabinoid Derived Pharmaceutical Revenue by Region (2021-2026)
6.2 APAC Cannabinoid Derived Pharmaceutical Sales by Type (2021-2026)
6.3 APAC Cannabinoid Derived Pharmaceutical Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Cannabinoid Derived Pharmaceutical by Country
7.1.1 Europe Cannabinoid Derived Pharmaceutical Sales by Country (2021-2026)
7.1.2 Europe Cannabinoid Derived Pharmaceutical Revenue by Country (2021-2026)
7.2 Europe Cannabinoid Derived Pharmaceutical Sales by Type (2021-2026)
7.3 Europe Cannabinoid Derived Pharmaceutical Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Cannabinoid Derived Pharmaceutical by Country
8.1.1 Middle East & Africa Cannabinoid Derived Pharmaceutical Sales by Country (2021-2026)
8.1.2 Middle East & Africa Cannabinoid Derived Pharmaceutical Revenue by Country (2021-2026)
8.2 Middle East & Africa Cannabinoid Derived Pharmaceutical Sales by Type (2021-2026)
8.3 Middle East & Africa Cannabinoid Derived Pharmaceutical Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Cannabinoid Derived Pharmaceutical
10.3 Manufacturing Process Analysis of Cannabinoid Derived Pharmaceutical
10.4 Industry Chain Structure of Cannabinoid Derived Pharmaceutical
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Cannabinoid Derived Pharmaceutical Distributors
11.3 Cannabinoid Derived Pharmaceutical Customer
12 WORLD FORECAST REVIEW FOR CANNABINOID DERIVED PHARMACEUTICAL BY GEOGRAPHIC REGION
12.1 Global Cannabinoid Derived Pharmaceutical Market Size Forecast by Region
12.1.1 Global Cannabinoid Derived Pharmaceutical Forecast by Region (2027-2032)
12.1.2 Global Cannabinoid Derived Pharmaceutical Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Cannabinoid Derived Pharmaceutical Forecast by Type (2027-2032)
12.7 Global Cannabinoid Derived Pharmaceutical Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Cara Therapeutics Inc
13.1.1 Cara Therapeutics Inc Company Information
13.1.2 Cara Therapeutics Inc Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.1.3 Cara Therapeutics Inc Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Cara Therapeutics Inc Main Business Overview
13.1.5 Cara Therapeutics Inc Latest Developments
13.2 Arena Pharmaceuticals
13.2.1 Arena Pharmaceuticals Company Information
13.2.2 Arena Pharmaceuticals Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.2.3 Arena Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Arena Pharmaceuticals Main Business Overview
13.2.5 Arena Pharmaceuticals Latest Developments
13.3 Cannabics Pharmaceuticals Inc
13.3.1 Cannabics Pharmaceuticals Inc Company Information
13.3.2 Cannabics Pharmaceuticals Inc Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.3.3 Cannabics Pharmaceuticals Inc Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Cannabics Pharmaceuticals Inc Main Business Overview
13.3.5 Cannabics Pharmaceuticals Inc Latest Developments
13.4 Echo Pharmaceuticals
13.4.1 Echo Pharmaceuticals Company Information
13.4.2 Echo Pharmaceuticals Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.4.3 Echo Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Echo Pharmaceuticals Main Business Overview
13.4.5 Echo Pharmaceuticals Latest Developments
13.5 Gw Pharmaceuticals
13.5.1 Gw Pharmaceuticals Company Information
13.5.2 Gw Pharmaceuticals Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.5.3 Gw Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Gw Pharmaceuticals Main Business Overview
13.5.5 Gw Pharmaceuticals Latest Developments
13.6 Inmed Pharmaceuticals
13.6.1 Inmed Pharmaceuticals Company Information
13.6.2 Inmed Pharmaceuticals Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.6.3 Inmed Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Inmed Pharmaceuticals Main Business Overview
13.6.5 Inmed Pharmaceuticals Latest Developments
13.7 Insys Therapeutics Inc
13.7.1 Insys Therapeutics Inc Company Information
13.7.2 Insys Therapeutics Inc Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.7.3 Insys Therapeutics Inc Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Insys Therapeutics Inc Main Business Overview
13.7.5 Insys Therapeutics Inc Latest Developments
13.8 Larapharm
13.8.1 Larapharm Company Information
13.8.2 Larapharm Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.8.3 Larapharm Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Larapharm Main Business Overview
13.8.5 Larapharm Latest Developments
13.9 Mgc Pharmaceuticals Ltd
13.9.1 Mgc Pharmaceuticals Ltd Company Information
13.9.2 Mgc Pharmaceuticals Ltd Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.9.3 Mgc Pharmaceuticals Ltd Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Mgc Pharmaceuticals Ltd Main Business Overview
13.9.5 Mgc Pharmaceuticals Ltd Latest Developments
13.10 One World Cannabis
13.10.1 One World Cannabis Company Information
13.10.2 One World Cannabis Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.10.3 One World Cannabis Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 One World Cannabis Main Business Overview
13.10.5 One World Cannabis Latest Developments
13.11 Orpheus Medica
13.11.1 Orpheus Medica Company Information
13.11.2 Orpheus Medica Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.11.3 Orpheus Medica Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Orpheus Medica Main Business Overview
13.11.5 Orpheus Medica Latest Developments
13.12 Receptor Life Sciences
13.12.1 Receptor Life Sciences Company Information
13.12.2 Receptor Life Sciences Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.12.3 Receptor Life Sciences Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Receptor Life Sciences Main Business Overview
13.12.5 Receptor Life Sciences Latest Developments
13.13 Respirerx Pharmaceuticals
13.13.1 Respirerx Pharmaceuticals Company Information
13.13.2 Respirerx Pharmaceuticals Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.13.3 Respirerx Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Respirerx Pharmaceuticals Main Business Overview
13.13.5 Respirerx Pharmaceuticals Latest Developments
13.14 Tetra Bio-Pharma
13.14.1 Tetra Bio-Pharma Company Information
13.14.2 Tetra Bio-Pharma Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.14.3 Tetra Bio-Pharma Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Tetra Bio-Pharma Main Business Overview
13.14.5 Tetra Bio-Pharma Latest Developments
13.15 Cardiol Therapeutics
13.15.1 Cardiol Therapeutics Company Information
13.15.2 Cardiol Therapeutics Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.15.3 Cardiol Therapeutics Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Cardiol Therapeutics Main Business Overview
13.15.5 Cardiol Therapeutics Latest Developments
13.16 United Cannabis Corporation
13.16.1 United Cannabis Corporation Company Information
13.16.2 United Cannabis Corporation Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.16.3 United Cannabis Corporation Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 United Cannabis Corporation Main Business Overview
13.16.5 United Cannabis Corporation Latest Developments
13.17 Zynerba Pharmaceuticals
13.17.1 Zynerba Pharmaceuticals Company Information
13.17.2 Zynerba Pharmaceuticals Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.17.3 Zynerba Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Zynerba Pharmaceuticals Main Business Overview
13.17.5 Zynerba Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Cannabinoid Derived Pharmaceutical Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Cannabinoid Derived Pharmaceutical Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Cannabinoid Receptor Type 1 (CB1)
Table 4. Major Players of Cannabinoid Receptor Type 2 (CB2)
Table 5. Major Players of Others
Table 6. Global Cannabinoid Derived Pharmaceutical Sales by Type (2021-2026) & (K Units)
Table 7. Global Cannabinoid Derived Pharmaceutical Sales Market Share by Type (2021-2026)
Table 8. Global Cannabinoid Derived Pharmaceutical Revenue by Type (2021-2026) & ($ million)
Table 9. Global Cannabinoid Derived Pharmaceutical Revenue Market Share by Type (2021-2026)
Table 10. Global Cannabinoid Derived Pharmaceutical Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Global Cannabinoid Derived Pharmaceutical Sale by Application (2021-2026) & (K Units)
Table 12. Global Cannabinoid Derived Pharmaceutical Sale Market Share by Application (2021-2026)
Table 13. Global Cannabinoid Derived Pharmaceutical Revenue by Application (2021-2026) & ($ million)
Table 14. Global Cannabinoid Derived Pharmaceutical Revenue Market Share by Application (2021-2026)
Table 15. Global Cannabinoid Derived Pharmaceutical Sale Price by Application (2021-2026) & (US$/Unit)
Table 16. Global Cannabinoid Derived Pharmaceutical Sales by Company (2021-2026) & (K Units)
Table 17. Global Cannabinoid Derived Pharmaceutical Sales Market Share by Company (2021-2026)
Table 18. Global Cannabinoid Derived Pharmaceutical Revenue by Company (2021-2026) & ($ millions)
Table 19. Global Cannabinoid Derived Pharmaceutical Revenue Market Share by Company (2021-2026)
Table 20. Global Cannabinoid Derived Pharmaceutical Sale Price by Company (2021-2026) & (US$/Unit)
Table 21. Key Manufacturers Cannabinoid Derived Pharmaceutical Producing Area Distribution and Sales Area
Table 22. Players Cannabinoid Derived Pharmaceutical Products Offered
Table 23. Cannabinoid Derived Pharmaceutical Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Cannabinoid Derived Pharmaceutical Sales by Geographic Region (2021-2026) & (K Units)
Table 27. Global Cannabinoid Derived Pharmaceutical Sales Market Share Geographic Region (2021-2026)
Table 28. Global Cannabinoid Derived Pharmaceutical Revenue by Geographic Region (2021-2026) & ($ millions)
Table 29. Global Cannabinoid Derived Pharmaceutical Revenue Market Share by Geographic Region (2021-2026)
Table 30. Global Cannabinoid Derived Pharmaceutical Sales by Country/Region (2021-2026) & (K Units)
Table 31. Global Cannabinoid Derived Pharmaceutical Sales Market Share by Country/Region (2021-2026)
Table 32. Global Cannabinoid Derived Pharmaceutical Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global Cannabinoid Derived Pharmaceutical Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas Cannabinoid Derived Pharmaceutical Sales by Country (2021-2026) & (K Units)
Table 35. Americas Cannabinoid Derived Pharmaceutical Sales Market Share by Country (2021-2026)
Table 36. Americas Cannabinoid Derived Pharmaceutical Revenue by Country (2021-2026) & ($ millions)
Table 37. Americas Cannabinoid Derived Pharmaceutical Sales by Type (2021-2026) & (K Units)
Table 38. Americas Cannabinoid Derived Pharmaceutical Sales by Application (2021-2026) & (K Units)
Table 39. APAC Cannabinoid Derived Pharmaceutical Sales by Region (2021-2026) & (K Units)
Table 40. APAC Cannabinoid Derived Pharmaceutical Sales Market Share by Region (2021-2026)
Table 41. APAC Cannabinoid Derived Pharmaceutical Revenue by Region (2021-2026) & ($ millions)
Table 42. APAC Cannabinoid Derived Pharmaceutical Sales by Type (2021-2026) & (K Units)
Table 43. APAC Cannabinoid Derived Pharmaceutical Sales by Application (2021-2026) & (K Units)
Table 44. Europe Cannabinoid Derived Pharmaceutical Sales by Country (2021-2026) & (K Units)
Table 45. Europe Cannabinoid Derived Pharmaceutical Revenue by Country (2021-2026) & ($ millions)
Table 46. Europe Cannabinoid Derived Pharmaceutical Sales by Type (2021-2026) & (K Units)
Table 47. Europe Cannabinoid Derived Pharmaceutical Sales by Application (2021-2026) & (K Units)
Table 48. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales by Country (2021-2026) & (K Units)
Table 49. Middle East & Africa Cannabinoid Derived Pharmaceutical Revenue Market Share by Country (2021-2026)
Table 50. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales by Type (2021-2026) & (K Units)
Table 51. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales by Application (2021-2026) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Cannabinoid Derived Pharmaceutical
Table 53. Key Market Challenges & Risks of Cannabinoid Derived Pharmaceutical
Table 54. Key Industry Trends of Cannabinoid Derived Pharmaceutical
Table 55. Cannabinoid Derived Pharmaceutical Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Cannabinoid Derived Pharmaceutical Distributors List
Table 58. Cannabinoid Derived Pharmaceutical Customer List
Table 59. Global Cannabinoid Derived Pharmaceutical Sales Forecast by Region (2027-2032) & (K Units)
Table 60. Global Cannabinoid Derived Pharmaceutical Revenue Forecast by Region (2027-2032) & ($ millions)
Table 61. Americas Cannabinoid Derived Pharmaceutical Sales Forecast by Country (2027-2032) & (K Units)
Table 62. Americas Cannabinoid Derived Pharmaceutical Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 63. APAC Cannabinoid Derived Pharmaceutical Sales Forecast by Region (2027-2032) & (K Units)
Table 64. APAC Cannabinoid Derived Pharmaceutical Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 65. Europe Cannabinoid Derived Pharmaceutical Sales Forecast by Country (2027-2032) & (K Units)
Table 66. Europe Cannabinoid Derived Pharmaceutical Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Middle East & Africa Cannabinoid Derived Pharmaceutical Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Global Cannabinoid Derived Pharmaceutical Sales Forecast by Type (2027-2032) & (K Units)
Table 70. Global Cannabinoid Derived Pharmaceutical Revenue Forecast by Type (2027-2032) & ($ millions)
Table 71. Global Cannabinoid Derived Pharmaceutical Sales Forecast by Application (2027-2032) & (K Units)
Table 72. Global Cannabinoid Derived Pharmaceutical Revenue Forecast by Application (2027-2032) & ($ millions)
Table 73. Cara Therapeutics Inc Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 74. Cara Therapeutics Inc Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 75. Cara Therapeutics Inc Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. Cara Therapeutics Inc Main Business
Table 77. Cara Therapeutics Inc Latest Developments
Table 78. Arena Pharmaceuticals Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 79. Arena Pharmaceuticals Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 80. Arena Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Arena Pharmaceuticals Main Business
Table 82. Arena Pharmaceuticals Latest Developments
Table 83. Cannabics Pharmaceuticals Inc Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 84. Cannabics Pharmaceuticals Inc Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 85. Cannabics Pharmaceuticals Inc Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Cannabics Pharmaceuticals Inc Main Business
Table 87. Cannabics Pharmaceuticals Inc Latest Developments
Table 88. Echo Pharmaceuticals Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 89. Echo Pharmaceuticals Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 90. Echo Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Echo Pharmaceuticals Main Business
Table 92. Echo Pharmaceuticals Latest Developments
Table 93. Gw Pharmaceuticals Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 94. Gw Pharmaceuticals Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 95. Gw Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Gw Pharmaceuticals Main Business
Table 97. Gw Pharmaceuticals Latest Developments
Table 98. Inmed Pharmaceuticals Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 99. Inmed Pharmaceuticals Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 100. Inmed Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Inmed Pharmaceuticals Main Business
Table 102. Inmed Pharmaceuticals Latest Developments
Table 103. Insys Therapeutics Inc Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 104. Insys Therapeutics Inc Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 105. Insys Therapeutics Inc Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Insys Therapeutics Inc Main Business
Table 107. Insys Therapeutics Inc Latest Developments
Table 108. Larapharm Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 109. Larapharm Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 110. Larapharm Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Larapharm Main Business
Table 112. Larapharm Latest Developments
Table 113. Mgc Pharmaceuticals Ltd Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 114. Mgc Pharmaceuticals Ltd Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 115. Mgc Pharmaceuticals Ltd Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Mgc Pharmaceuticals Ltd Main Business
Table 117. Mgc Pharmaceuticals Ltd Latest Developments
Table 118. One World Cannabis Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 119. One World Cannabis Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 120. One World Cannabis Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. One World Cannabis Main Business
Table 122. One World Cannabis Latest Developments
Table 123. Orpheus Medica Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 124. Orpheus Medica Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 125. Orpheus Medica Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 126. Orpheus Medica Main Business
Table 127. Orpheus Medica Latest Developments
Table 128. Receptor Life Sciences Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 129. Receptor Life Sciences Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 130. Receptor Life Sciences Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 131. Receptor Life Sciences Main Business
Table 132. Receptor Life Sciences Latest Developments
Table 133. Respirerx Pharmaceuticals Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 134. Respirerx Pharmaceuticals Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 135. Respirerx Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 136. Respirerx Pharmaceuticals Main Business
Table 137. Respirerx Pharmaceuticals Latest Developments
Table 138. Tetra Bio-Pharma Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 139. Tetra Bio-Pharma Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 140. Tetra Bio-Pharma Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 141. Tetra Bio-Pharma Main Business
Table 142. Tetra Bio-Pharma Latest Developments
Table 143. Cardiol Therapeutics Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 144. Cardiol Therapeutics Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 145. Cardiol Therapeutics Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 146. Cardiol Therapeutics Main Business
Table 147. Cardiol Therapeutics Latest Developments
Table 148. United Cannabis Corporation Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 149. United Cannabis Corporation Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 150. United Cannabis Corporation Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 151. United Cannabis Corporation Main Business
Table 152. United Cannabis Corporation Latest Developments
Table 153. Zynerba Pharmaceuticals Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 154. Zynerba Pharmaceuticals Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 155. Zynerba Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 156. Zynerba Pharmaceuticals Main Business
Table 157. Zynerba Pharmaceuticals Latest Developments
Table 1. Cannabinoid Derived Pharmaceutical Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Cannabinoid Derived Pharmaceutical Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Cannabinoid Receptor Type 1 (CB1)
Table 4. Major Players of Cannabinoid Receptor Type 2 (CB2)
Table 5. Major Players of Others
Table 6. Global Cannabinoid Derived Pharmaceutical Sales by Type (2021-2026) & (K Units)
Table 7. Global Cannabinoid Derived Pharmaceutical Sales Market Share by Type (2021-2026)
Table 8. Global Cannabinoid Derived Pharmaceutical Revenue by Type (2021-2026) & ($ million)
Table 9. Global Cannabinoid Derived Pharmaceutical Revenue Market Share by Type (2021-2026)
Table 10. Global Cannabinoid Derived Pharmaceutical Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Global Cannabinoid Derived Pharmaceutical Sale by Application (2021-2026) & (K Units)
Table 12. Global Cannabinoid Derived Pharmaceutical Sale Market Share by Application (2021-2026)
Table 13. Global Cannabinoid Derived Pharmaceutical Revenue by Application (2021-2026) & ($ million)
Table 14. Global Cannabinoid Derived Pharmaceutical Revenue Market Share by Application (2021-2026)
Table 15. Global Cannabinoid Derived Pharmaceutical Sale Price by Application (2021-2026) & (US$/Unit)
Table 16. Global Cannabinoid Derived Pharmaceutical Sales by Company (2021-2026) & (K Units)
Table 17. Global Cannabinoid Derived Pharmaceutical Sales Market Share by Company (2021-2026)
Table 18. Global Cannabinoid Derived Pharmaceutical Revenue by Company (2021-2026) & ($ millions)
Table 19. Global Cannabinoid Derived Pharmaceutical Revenue Market Share by Company (2021-2026)
Table 20. Global Cannabinoid Derived Pharmaceutical Sale Price by Company (2021-2026) & (US$/Unit)
Table 21. Key Manufacturers Cannabinoid Derived Pharmaceutical Producing Area Distribution and Sales Area
Table 22. Players Cannabinoid Derived Pharmaceutical Products Offered
Table 23. Cannabinoid Derived Pharmaceutical Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Cannabinoid Derived Pharmaceutical Sales by Geographic Region (2021-2026) & (K Units)
Table 27. Global Cannabinoid Derived Pharmaceutical Sales Market Share Geographic Region (2021-2026)
Table 28. Global Cannabinoid Derived Pharmaceutical Revenue by Geographic Region (2021-2026) & ($ millions)
Table 29. Global Cannabinoid Derived Pharmaceutical Revenue Market Share by Geographic Region (2021-2026)
Table 30. Global Cannabinoid Derived Pharmaceutical Sales by Country/Region (2021-2026) & (K Units)
Table 31. Global Cannabinoid Derived Pharmaceutical Sales Market Share by Country/Region (2021-2026)
Table 32. Global Cannabinoid Derived Pharmaceutical Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global Cannabinoid Derived Pharmaceutical Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas Cannabinoid Derived Pharmaceutical Sales by Country (2021-2026) & (K Units)
Table 35. Americas Cannabinoid Derived Pharmaceutical Sales Market Share by Country (2021-2026)
Table 36. Americas Cannabinoid Derived Pharmaceutical Revenue by Country (2021-2026) & ($ millions)
Table 37. Americas Cannabinoid Derived Pharmaceutical Sales by Type (2021-2026) & (K Units)
Table 38. Americas Cannabinoid Derived Pharmaceutical Sales by Application (2021-2026) & (K Units)
Table 39. APAC Cannabinoid Derived Pharmaceutical Sales by Region (2021-2026) & (K Units)
Table 40. APAC Cannabinoid Derived Pharmaceutical Sales Market Share by Region (2021-2026)
Table 41. APAC Cannabinoid Derived Pharmaceutical Revenue by Region (2021-2026) & ($ millions)
Table 42. APAC Cannabinoid Derived Pharmaceutical Sales by Type (2021-2026) & (K Units)
Table 43. APAC Cannabinoid Derived Pharmaceutical Sales by Application (2021-2026) & (K Units)
Table 44. Europe Cannabinoid Derived Pharmaceutical Sales by Country (2021-2026) & (K Units)
Table 45. Europe Cannabinoid Derived Pharmaceutical Revenue by Country (2021-2026) & ($ millions)
Table 46. Europe Cannabinoid Derived Pharmaceutical Sales by Type (2021-2026) & (K Units)
Table 47. Europe Cannabinoid Derived Pharmaceutical Sales by Application (2021-2026) & (K Units)
Table 48. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales by Country (2021-2026) & (K Units)
Table 49. Middle East & Africa Cannabinoid Derived Pharmaceutical Revenue Market Share by Country (2021-2026)
Table 50. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales by Type (2021-2026) & (K Units)
Table 51. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales by Application (2021-2026) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Cannabinoid Derived Pharmaceutical
Table 53. Key Market Challenges & Risks of Cannabinoid Derived Pharmaceutical
Table 54. Key Industry Trends of Cannabinoid Derived Pharmaceutical
Table 55. Cannabinoid Derived Pharmaceutical Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Cannabinoid Derived Pharmaceutical Distributors List
Table 58. Cannabinoid Derived Pharmaceutical Customer List
Table 59. Global Cannabinoid Derived Pharmaceutical Sales Forecast by Region (2027-2032) & (K Units)
Table 60. Global Cannabinoid Derived Pharmaceutical Revenue Forecast by Region (2027-2032) & ($ millions)
Table 61. Americas Cannabinoid Derived Pharmaceutical Sales Forecast by Country (2027-2032) & (K Units)
Table 62. Americas Cannabinoid Derived Pharmaceutical Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 63. APAC Cannabinoid Derived Pharmaceutical Sales Forecast by Region (2027-2032) & (K Units)
Table 64. APAC Cannabinoid Derived Pharmaceutical Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 65. Europe Cannabinoid Derived Pharmaceutical Sales Forecast by Country (2027-2032) & (K Units)
Table 66. Europe Cannabinoid Derived Pharmaceutical Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Middle East & Africa Cannabinoid Derived Pharmaceutical Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Global Cannabinoid Derived Pharmaceutical Sales Forecast by Type (2027-2032) & (K Units)
Table 70. Global Cannabinoid Derived Pharmaceutical Revenue Forecast by Type (2027-2032) & ($ millions)
Table 71. Global Cannabinoid Derived Pharmaceutical Sales Forecast by Application (2027-2032) & (K Units)
Table 72. Global Cannabinoid Derived Pharmaceutical Revenue Forecast by Application (2027-2032) & ($ millions)
Table 73. Cara Therapeutics Inc Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 74. Cara Therapeutics Inc Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 75. Cara Therapeutics Inc Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. Cara Therapeutics Inc Main Business
Table 77. Cara Therapeutics Inc Latest Developments
Table 78. Arena Pharmaceuticals Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 79. Arena Pharmaceuticals Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 80. Arena Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Arena Pharmaceuticals Main Business
Table 82. Arena Pharmaceuticals Latest Developments
Table 83. Cannabics Pharmaceuticals Inc Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 84. Cannabics Pharmaceuticals Inc Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 85. Cannabics Pharmaceuticals Inc Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Cannabics Pharmaceuticals Inc Main Business
Table 87. Cannabics Pharmaceuticals Inc Latest Developments
Table 88. Echo Pharmaceuticals Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 89. Echo Pharmaceuticals Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 90. Echo Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Echo Pharmaceuticals Main Business
Table 92. Echo Pharmaceuticals Latest Developments
Table 93. Gw Pharmaceuticals Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 94. Gw Pharmaceuticals Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 95. Gw Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Gw Pharmaceuticals Main Business
Table 97. Gw Pharmaceuticals Latest Developments
Table 98. Inmed Pharmaceuticals Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 99. Inmed Pharmaceuticals Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 100. Inmed Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Inmed Pharmaceuticals Main Business
Table 102. Inmed Pharmaceuticals Latest Developments
Table 103. Insys Therapeutics Inc Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 104. Insys Therapeutics Inc Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 105. Insys Therapeutics Inc Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Insys Therapeutics Inc Main Business
Table 107. Insys Therapeutics Inc Latest Developments
Table 108. Larapharm Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 109. Larapharm Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 110. Larapharm Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Larapharm Main Business
Table 112. Larapharm Latest Developments
Table 113. Mgc Pharmaceuticals Ltd Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 114. Mgc Pharmaceuticals Ltd Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 115. Mgc Pharmaceuticals Ltd Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Mgc Pharmaceuticals Ltd Main Business
Table 117. Mgc Pharmaceuticals Ltd Latest Developments
Table 118. One World Cannabis Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 119. One World Cannabis Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 120. One World Cannabis Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. One World Cannabis Main Business
Table 122. One World Cannabis Latest Developments
Table 123. Orpheus Medica Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 124. Orpheus Medica Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 125. Orpheus Medica Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 126. Orpheus Medica Main Business
Table 127. Orpheus Medica Latest Developments
Table 128. Receptor Life Sciences Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 129. Receptor Life Sciences Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 130. Receptor Life Sciences Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 131. Receptor Life Sciences Main Business
Table 132. Receptor Life Sciences Latest Developments
Table 133. Respirerx Pharmaceuticals Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 134. Respirerx Pharmaceuticals Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 135. Respirerx Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 136. Respirerx Pharmaceuticals Main Business
Table 137. Respirerx Pharmaceuticals Latest Developments
Table 138. Tetra Bio-Pharma Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 139. Tetra Bio-Pharma Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 140. Tetra Bio-Pharma Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 141. Tetra Bio-Pharma Main Business
Table 142. Tetra Bio-Pharma Latest Developments
Table 143. Cardiol Therapeutics Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 144. Cardiol Therapeutics Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 145. Cardiol Therapeutics Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 146. Cardiol Therapeutics Main Business
Table 147. Cardiol Therapeutics Latest Developments
Table 148. United Cannabis Corporation Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 149. United Cannabis Corporation Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 150. United Cannabis Corporation Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 151. United Cannabis Corporation Main Business
Table 152. United Cannabis Corporation Latest Developments
Table 153. Zynerba Pharmaceuticals Basic Information, Cannabinoid Derived Pharmaceutical Manufacturing Base, Sales Area and Its Competitors
Table 154. Zynerba Pharmaceuticals Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
Table 155. Zynerba Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 156. Zynerba Pharmaceuticals Main Business
Table 157. Zynerba Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Picture of Cannabinoid Derived Pharmaceutical
Figure 2. Cannabinoid Derived Pharmaceutical Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Cannabinoid Derived Pharmaceutical Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Cannabinoid Derived Pharmaceutical Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Cannabinoid Derived Pharmaceutical Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Cannabinoid Derived Pharmaceutical Sales Market Share by Country/Region (2025)
Figure 10. Cannabinoid Derived Pharmaceutical Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Cannabinoid Receptor Type 1 (CB1)
Figure 12. Product Picture of Cannabinoid Receptor Type 2 (CB2)
Figure 13. Product Picture of Others
Figure 14. Global Cannabinoid Derived Pharmaceutical Sales Market Share by Type in 2026
Figure 15. Global Cannabinoid Derived Pharmaceutical Revenue Market Share by Type (2021-2026)
Figure 16. Cannabinoid Derived Pharmaceutical Consumed in Epilepsy
Figure 17. Global Cannabinoid Derived Pharmaceutical Market: Epilepsy (2021-2026) & (K Units)
Figure 18. Cannabinoid Derived Pharmaceutical Consumed in Migraine
Figure 19. Global Cannabinoid Derived Pharmaceutical Market: Migraine (2021-2026) & (K Units)
Figure 20. Cannabinoid Derived Pharmaceutical Consumed in Multiple Sclerosis
Figure 21. Global Cannabinoid Derived Pharmaceutical Market: Multiple Sclerosis (2021-2026) & (K Units)
Figure 22. Cannabinoid Derived Pharmaceutical Consumed in Others
Figure 23. Global Cannabinoid Derived Pharmaceutical Market: Others (2021-2026) & (K Units)
Figure 24. Global Cannabinoid Derived Pharmaceutical Sale Market Share by Application (2025)
Figure 25. Global Cannabinoid Derived Pharmaceutical Revenue Market Share by Application in 2026
Figure 26. Cannabinoid Derived Pharmaceutical Sales by Company in 2026 (K Units)
Figure 27. Global Cannabinoid Derived Pharmaceutical Sales Market Share by Company in 2026
Figure 28. Cannabinoid Derived Pharmaceutical Revenue by Company in 2026 ($ millions)
Figure 29. Global Cannabinoid Derived Pharmaceutical Revenue Market Share by Company in 2026
Figure 30. Global Cannabinoid Derived Pharmaceutical Sales Market Share by Geographic Region (2021-2026)
Figure 31. Global Cannabinoid Derived Pharmaceutical Revenue Market Share by Geographic Region in 2026
Figure 32. Americas Cannabinoid Derived Pharmaceutical Sales 2021-2026 (K Units)
Figure 33. Americas Cannabinoid Derived Pharmaceutical Revenue 2021-2026 ($ millions)
Figure 34. APAC Cannabinoid Derived Pharmaceutical Sales 2021-2026 (K Units)
Figure 35. APAC Cannabinoid Derived Pharmaceutical Revenue 2021-2026 ($ millions)
Figure 36. Europe Cannabinoid Derived Pharmaceutical Sales 2021-2026 (K Units)
Figure 37. Europe Cannabinoid Derived Pharmaceutical Revenue 2021-2026 ($ millions)
Figure 38. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales 2021-2026 (K Units)
Figure 39. Middle East & Africa Cannabinoid Derived Pharmaceutical Revenue 2021-2026 ($ millions)
Figure 40. Americas Cannabinoid Derived Pharmaceutical Sales Market Share by Country in 2026
Figure 41. Americas Cannabinoid Derived Pharmaceutical Revenue Market Share by Country (2021-2026)
Figure 42. Americas Cannabinoid Derived Pharmaceutical Sales Market Share by Type (2021-2026)
Figure 43. Americas Cannabinoid Derived Pharmaceutical Sales Market Share by Application (2021-2026)
Figure 44. United States Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 45. Canada Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 46. Mexico Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 47. Brazil Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 48. APAC Cannabinoid Derived Pharmaceutical Sales Market Share by Region in 2026
Figure 49. APAC Cannabinoid Derived Pharmaceutical Revenue Market Share by Region (2021-2026)
Figure 50. APAC Cannabinoid Derived Pharmaceutical Sales Market Share by Type (2021-2026)
Figure 51. APAC Cannabinoid Derived Pharmaceutical Sales Market Share by Application (2021-2026)
Figure 52. China Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 53. Japan Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 54. South Korea Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 55. Southeast Asia Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 56. India Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 57. Australia Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 58. China Taiwan Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 59. Europe Cannabinoid Derived Pharmaceutical Sales Market Share by Country in 2026
Figure 60. Europe Cannabinoid Derived Pharmaceutical Revenue Market Share by Country (2021-2026)
Figure 61. Europe Cannabinoid Derived Pharmaceutical Sales Market Share by Type (2021-2026)
Figure 62. Europe Cannabinoid Derived Pharmaceutical Sales Market Share by Application (2021-2026)
Figure 63. Germany Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 64. France Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 65. UK Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 66. Italy Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 67. Russia Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 68. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Market Share by Country (2021-2026)
Figure 69. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Market Share by Type (2021-2026)
Figure 70. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Market Share by Application (2021-2026)
Figure 71. Egypt Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 72. South Africa Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 73. Israel Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 74. Turkey Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 75. GCC Countries Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 76. Manufacturing Cost Structure Analysis of Cannabinoid Derived Pharmaceutical in 2026
Figure 77. Manufacturing Process Analysis of Cannabinoid Derived Pharmaceutical
Figure 78. Industry Chain Structure of Cannabinoid Derived Pharmaceutical
Figure 79. Channels of Distribution
Figure 80. Global Cannabinoid Derived Pharmaceutical Sales Market Forecast by Region (2027-2032)
Figure 81. Global Cannabinoid Derived Pharmaceutical Revenue Market Share Forecast by Region (2027-2032)
Figure 82. Global Cannabinoid Derived Pharmaceutical Sales Market Share Forecast by Type (2027-2032)
Figure 83. Global Cannabinoid Derived Pharmaceutical Revenue Market Share Forecast by Type (2027-2032)
Figure 84. Global Cannabinoid Derived Pharmaceutical Sales Market Share Forecast by Application (2027-2032)
Figure 85. Global Cannabinoid Derived Pharmaceutical Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Cannabinoid Derived Pharmaceutical
Figure 2. Cannabinoid Derived Pharmaceutical Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Cannabinoid Derived Pharmaceutical Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Cannabinoid Derived Pharmaceutical Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Cannabinoid Derived Pharmaceutical Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Cannabinoid Derived Pharmaceutical Sales Market Share by Country/Region (2025)
Figure 10. Cannabinoid Derived Pharmaceutical Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Cannabinoid Receptor Type 1 (CB1)
Figure 12. Product Picture of Cannabinoid Receptor Type 2 (CB2)
Figure 13. Product Picture of Others
Figure 14. Global Cannabinoid Derived Pharmaceutical Sales Market Share by Type in 2026
Figure 15. Global Cannabinoid Derived Pharmaceutical Revenue Market Share by Type (2021-2026)
Figure 16. Cannabinoid Derived Pharmaceutical Consumed in Epilepsy
Figure 17. Global Cannabinoid Derived Pharmaceutical Market: Epilepsy (2021-2026) & (K Units)
Figure 18. Cannabinoid Derived Pharmaceutical Consumed in Migraine
Figure 19. Global Cannabinoid Derived Pharmaceutical Market: Migraine (2021-2026) & (K Units)
Figure 20. Cannabinoid Derived Pharmaceutical Consumed in Multiple Sclerosis
Figure 21. Global Cannabinoid Derived Pharmaceutical Market: Multiple Sclerosis (2021-2026) & (K Units)
Figure 22. Cannabinoid Derived Pharmaceutical Consumed in Others
Figure 23. Global Cannabinoid Derived Pharmaceutical Market: Others (2021-2026) & (K Units)
Figure 24. Global Cannabinoid Derived Pharmaceutical Sale Market Share by Application (2025)
Figure 25. Global Cannabinoid Derived Pharmaceutical Revenue Market Share by Application in 2026
Figure 26. Cannabinoid Derived Pharmaceutical Sales by Company in 2026 (K Units)
Figure 27. Global Cannabinoid Derived Pharmaceutical Sales Market Share by Company in 2026
Figure 28. Cannabinoid Derived Pharmaceutical Revenue by Company in 2026 ($ millions)
Figure 29. Global Cannabinoid Derived Pharmaceutical Revenue Market Share by Company in 2026
Figure 30. Global Cannabinoid Derived Pharmaceutical Sales Market Share by Geographic Region (2021-2026)
Figure 31. Global Cannabinoid Derived Pharmaceutical Revenue Market Share by Geographic Region in 2026
Figure 32. Americas Cannabinoid Derived Pharmaceutical Sales 2021-2026 (K Units)
Figure 33. Americas Cannabinoid Derived Pharmaceutical Revenue 2021-2026 ($ millions)
Figure 34. APAC Cannabinoid Derived Pharmaceutical Sales 2021-2026 (K Units)
Figure 35. APAC Cannabinoid Derived Pharmaceutical Revenue 2021-2026 ($ millions)
Figure 36. Europe Cannabinoid Derived Pharmaceutical Sales 2021-2026 (K Units)
Figure 37. Europe Cannabinoid Derived Pharmaceutical Revenue 2021-2026 ($ millions)
Figure 38. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales 2021-2026 (K Units)
Figure 39. Middle East & Africa Cannabinoid Derived Pharmaceutical Revenue 2021-2026 ($ millions)
Figure 40. Americas Cannabinoid Derived Pharmaceutical Sales Market Share by Country in 2026
Figure 41. Americas Cannabinoid Derived Pharmaceutical Revenue Market Share by Country (2021-2026)
Figure 42. Americas Cannabinoid Derived Pharmaceutical Sales Market Share by Type (2021-2026)
Figure 43. Americas Cannabinoid Derived Pharmaceutical Sales Market Share by Application (2021-2026)
Figure 44. United States Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 45. Canada Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 46. Mexico Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 47. Brazil Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 48. APAC Cannabinoid Derived Pharmaceutical Sales Market Share by Region in 2026
Figure 49. APAC Cannabinoid Derived Pharmaceutical Revenue Market Share by Region (2021-2026)
Figure 50. APAC Cannabinoid Derived Pharmaceutical Sales Market Share by Type (2021-2026)
Figure 51. APAC Cannabinoid Derived Pharmaceutical Sales Market Share by Application (2021-2026)
Figure 52. China Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 53. Japan Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 54. South Korea Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 55. Southeast Asia Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 56. India Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 57. Australia Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 58. China Taiwan Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 59. Europe Cannabinoid Derived Pharmaceutical Sales Market Share by Country in 2026
Figure 60. Europe Cannabinoid Derived Pharmaceutical Revenue Market Share by Country (2021-2026)
Figure 61. Europe Cannabinoid Derived Pharmaceutical Sales Market Share by Type (2021-2026)
Figure 62. Europe Cannabinoid Derived Pharmaceutical Sales Market Share by Application (2021-2026)
Figure 63. Germany Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 64. France Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 65. UK Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 66. Italy Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 67. Russia Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 68. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Market Share by Country (2021-2026)
Figure 69. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Market Share by Type (2021-2026)
Figure 70. Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Market Share by Application (2021-2026)
Figure 71. Egypt Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 72. South Africa Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 73. Israel Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 74. Turkey Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 75. GCC Countries Cannabinoid Derived Pharmaceutical Revenue Growth 2021-2026 ($ millions)
Figure 76. Manufacturing Cost Structure Analysis of Cannabinoid Derived Pharmaceutical in 2026
Figure 77. Manufacturing Process Analysis of Cannabinoid Derived Pharmaceutical
Figure 78. Industry Chain Structure of Cannabinoid Derived Pharmaceutical
Figure 79. Channels of Distribution
Figure 80. Global Cannabinoid Derived Pharmaceutical Sales Market Forecast by Region (2027-2032)
Figure 81. Global Cannabinoid Derived Pharmaceutical Revenue Market Share Forecast by Region (2027-2032)
Figure 82. Global Cannabinoid Derived Pharmaceutical Sales Market Share Forecast by Type (2027-2032)
Figure 83. Global Cannabinoid Derived Pharmaceutical Revenue Market Share Forecast by Type (2027-2032)
Figure 84. Global Cannabinoid Derived Pharmaceutical Sales Market Share Forecast by Application (2027-2032)
Figure 85. Global Cannabinoid Derived Pharmaceutical Revenue Market Share Forecast by Application (2027-2032)
